The use of original ex vivo immunoadsorption and " multi-manner" apheresis in ABO/H-mismatched kidney transplants-A phase II clinical study

Transfusion and Apheresis Science

Volumn 43, Issue 2, 2010, Pages 141-148

  Balint, Bela ^a,b   Pavlovic, Mirjana ^c   Todorovic, Milena ^d   Jevtic, Miodrag ^e   Ristanovic, Elizabeta ^e   Ignjatovic, Ljiljana ^f  

^a Institute of Transfusiology   (Serbia)

^b UNIVERSITY OF BELGRADE   (Serbia)

^c FLORIDA ATLANTIC UNIVERSITY   (United States)

^d University Clinical Center   (Serbia)

^e Head Office of MMA   (Serbia)

^f Clinic for Nephrology of MMA   (Serbia)

Author keywords

ABO incompatibility; Immunoadsorption; Kidney; Transplantation

Indexed keywords

CREATININE; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; STEROID; TACROLIMUS;

ADULT; ANEMIA; APHERESIS; ARTICLE; BLEEDING; BLOOD GROUP ABO INCOMPATIBILITY; BLOOD GROUP INCOMPATIBILITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; EXTRACORPOREAL IMMUNOADSORPTION; FEMALE; FOLLOW UP; HUMAN; IMMUNOADSORPTION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MEDICAL INSTRUMENTATION; ORGAN TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PLASMAPHERESIS; POSTOPERATIVE CARE; PREOPERATIVE CARE; SEPSIS; TREATMENT OUTCOME;

ABO BLOOD-GROUP SYSTEM; ADSORPTION; ADULT; ANTIGENS, CD20; BLOOD GROUP INCOMPATIBILITY; FEMALE; HUMANS; IMMUNE SYSTEM; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; STEROIDS; TACROLIMUS; TIME FACTORS;

EID: 77958151784     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2010.07.002     Document Type: Article

References (20)

1. Balint B., National Apheresis Group Apheresis in donor and therapeutic settings: recruitments vs. possibilities - a multicenter study. Transfus Apher Sci 2005, 33:229-237.
2. Vamvakas E.C., Pineda A.A. Selective extraction of plasma constituents. Apheresis: principles and practice 2003, 437-476. AABB Press, Bethesda. 2nd ed. B.C. McLeod, T.H. Price, R. Weinstein (Eds.).
3. Balint B., Ostojic G., Pavlovic M., Hrvacevic R., Pavlovic M., Tukic Lj, et al. Cytapheresis in the treatment of cell-affected blood disorders and abnormalities. Transfus Apher Sci 2006, 35:25-31.
4. Takahashi K., Saito K., Takahara S., Okuyama A., Tanabe K., Toma H., et al. Excellent long term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004, 4:1089-1096.
5. Takahashi K., Saito K. Present status of ABO-incompatible kidney transplantation in Japan. Xenotransplantation 2006, 13:118-122.
6. Tyden G., Kumlien G., Genberg H., Sandberg J., Lundgren T., Fehrman I. ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab. Am J Transplant 2005, 5:145-148.
7. Kumlien G., Ullström L., Losvall A., Persson L.G., Tyden G. Clinical experience with a new apheresis filter that specifically depletes ABO blood group antibodies. Transfusion 2006, 46:1568-1575.
8. Tyden G., Kumlien G., Genberg H., Sandberg J., Sedigh A., Lundgren T., et al. The Stockholm experience with ABO-incompatible kidney transplantation without splenectomy. Xenotransplantation 2006, 13:105-107.
9. Schwartz J., Stegall M.D., Kremers W.K., Gloor J. Complications, resource utilization, and cost of ABO-incompatible living donor kidney transplantation. Transplantation 2006, 82:164-165.
10. Balint B., Pavlovic M., Jevtic M., Hrvacevic R., Ignjatovic L., Ostojic G., et al. Simple " closed-circuit" group-specific immunoadsorption system for ABO-incompatible kidney transplants. Transfus Apher Sci 2007, 36:225-233.
11. Todorovic M., Balint B., Suvajdzic N., Pavlovic M., Petrovic M., Jevtic M., et al. Triple-way therapeutic approach for paraganglioma-dependent erythrocytosis: drugs plus surgery plus " multi-manner" apheresis. Med Oncol 2008, 25(2):148-153.
12. Tobian A.A., Shirey R.S., Montgomery R.A., Ness P.M., King K.E. The critical role of plasmapheresis in ABO-incompatible renal transplantation. Transfusion 2008, 48(11):2453-2460.
13. Winters J.L., Gloor J.M., Pineda A.A., Stegall M.D., Moore S.B. Plasma exchange conditioning for ABO-incompatible renal transplantation. J Clin Apher 2004, 19:79-85.
14. Balint B., Radovic M., Taseski J., Calija B. Investigation of the hydrosoluble type group-specific ABH and Lewis substances. Acta Antropol Yugoslav 1986, 23:5-12.
15. Stamatovic D., Tukic Lj., Balint B., Tarabar O., Elez M., Simic Lj, et al. Does donor-recipient ABO incompatibility have impact on the outcome following HLA-identical sibling haematopoietic stem cell transplantation. Bone Marrow Transplant 2004, 33(Suppl. 1):132-190.
16. Ivanovski N., Popov Z., Masin-Spasovska J., Dimcevska A.H., Kolevski P. First two ABO-incompatible living renal transplantations using splenectomy, rituximab, plasmapheresis and IVIG as a preconditioning regimen: a single center experience in the Balkans. Xenotransplantation 2006, 13:123-125.
17. Stegall M.D., Gloor J., Winters J.L., Moore S.B., Degoey S. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2006, 6:346-351.
18. Venetz J.P., Pascual M. New treatments for acute humoral rejection of kidney allografts. Expert Opin Investig Drugs 2007, 16:625-633.
19. Wilpert J., Geyer M., Teschner S., Schaefer T., Pisarski P., Schulz-Huotari C., et al. ABO-incompatible kidney transplantation-proposal of an intensified apheresis strategy for patients with high initial isoagglutinine titers. J Clin Apher 2007, 22:314-322.
20. Rydberg L. ABO-incompatibility in solid organ transplantation. Transfus Med 2001, 11:325-342.